Investigating the role of SOX11 in aggressive B-cell lymphoma
Targeting SOX11 in Mantle Cell Lymphoma
This study is looking at how a protein called SOX11 affects the growth of Mantle Cell Lymphoma, a serious type of blood cancer, using special mouse models to help find new ways to treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10854812 on NIH RePORTER |
What this research studies
This research focuses on understanding how the SOX11 transcription factor contributes to the development and progression of Mantle Cell Lymphoma (MCL), a severe form of B-cell Non-Hodgkin's Lymphoma. By utilizing specially developed mouse models that mimic human MCL, the researchers aim to explore the interactions between SOX11 and other genetic factors like Cyclin D1. The study will involve analyzing the behavior of B cells in these models to uncover mechanisms that drive the disease. Patients may benefit from insights gained that could lead to new treatment strategies targeting SOX11.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Mantle Cell Lymphoma or those at risk for developing this aggressive form of cancer.
Not a fit: Patients with other types of Non-Hodgkin's Lymphoma or those without a diagnosis of B-cell malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that specifically target SOX11, improving outcomes for patients with Mantle Cell Lymphoma.
How similar studies have performed: Previous research has shown promising results in targeting genetic factors in lymphoma, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Parekh, Samir — Icahn School of Medicine at Mount Sinai
- Study coordinator: Parekh, Samir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.